Olaparib plus abiraterone as first-line therapy in men with metastatic castration-resistant prostate cancer: Pharmacokinetics data from the PROpel trial
Armstrong, A. J. Thiery-Vuillemin, A. Oya, M. Procopio, G. De Menezes, J. J. Girotto, G. C. Ghatalia, P. Din, F. N. O. Spiegelhalder, P.
Armstrong, A. J.
Thiery-Vuillemin, A.
Oya, M.
Procopio, G.
De Menezes, J. J.
Girotto, G. C.
Ghatalia, P.
Din, F. N. O.
Spiegelhalder, P.
Citations
Altmetric:
Abstract
Affiliation
Description
Date
2022
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Armstrong AJ, Clarke NW, Thiery-Vuillemin A, Oya M, Procopio G, De Menezes JJ, et al. Olaparib plus abiraterone as first-line therapy in men with metastatic castration-resistant prostate cancer: Pharmacokinetics data from the PROpel trial. Journal of Clinical Oncology. 2022 Jun;40(16). PubMed PMID: WOS:000863680301470.